Pensacola, FL Â- ActiGraph, a leading provider of wearable activity and sleep measurement solutions for the global pharmaceutical industry and academic research community, has announced the upcoming launch of the CentrePoint Data Hub, a homeÂbased communication gateway that securely transmits data captured by ActiGraph activity monitors and other connected health devices to the CentrePoint cloud software platform via cellular network. The CentrePoint Data Hub is an extension of ActiGraph’s CentrePoint platform, a webÂbased technology suite used to deploy and manage activity monitor data collection within clinical development and health research environments. The CentrePoint Data Hub provides a simple, flexible way for clinical trial and research study participants to share their physical activity and sleep information with the study team from the comfort of home, without the need for a PC or smartphone. The plugÂandÂplay CentrePoint Data Hub syncs with ActiGraph activity monitors using USB 2.0 or Bluetooth LE, and collected data is seamlessly uploaded to the CentrePoint system via 3G cellular network. Participant data is immediately accessible through the CentrePoint web portal, providing the research team with an opportunity to quickly intervene if costly and timeÂconsuming noncompliance issues arise. RealÂtime participant measures can also be used to inform earlier clinical decision making and support adaptive trial designs. “The CentrePoint Data Hub was developed with two specific goals in mind,” said Jeremy Wyatt, ActiGraph CTO and Senior Vice President of Product Development. “We set out to build a solution that provides our pharma and research clients with actionable, realÂtime information that has the potential to impact the success of a trial. Secondly, and just as important, our solution had to be practically effortless on the part of the participants, who may already be burdened with numerous other tests and procedures.” “We see a lot of interest from pharmaceutical clinical trial sponsors in capturing objective activity and sleep information from clinical trial patients in real time,” said James Munz, Vice President of Innovation at ERT. “This is exactly the type of solution we are exploring in our Innovation Lab â one that offers the potential for pharmaceutical companies and clinical research organizations to improve clinical trial data collection through the use of validated mHealth devices during new medical product development.” About ActiGraph ActiGraph’s extensively validated suite of hardware and software products are widely used by prominent scientific, academic, and pharmaceutical organizations in more than 75 countries in research studies and clinical trials involving physical activity, sedentary behavior, energy expenditure, and sleep/wake behavior. ActiGraph measurement solutions have delivered objective activity and sleep measures to many high profile population studies including the National Health and Nutrition Examination Survey (NHANES), the Harvard Women’s Health Study, the German National Cohort, and the U.K. Millennium Cohort Study.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.